Psychiatry Investig Search

CLOSE


Psychiatry Investig > Volume 23(9); 2026 > Article
Feng, Zhang, Fan, Tang, and Zhang: The Thought Induction Psychotherapy Technique’s Clinical Effectiveness in Treating Adolescent Depression and Anxiety: A Randomized Controlled Trial

Abstract

Objective

We evaluated the clinical effectiveness of low resistance state thought induction psychotherapy (TIP) in treating adolescent depression and anxiety.

Methods

This study was registered in the Chinese Clinical Trial Registry (ChiCTR2600119490). One hundred adolescent patients with depression and anxiety admitted to hospital between January 2022 and December 2023 was randomly divided into a control and an experimental group, with 50 cases in each group. The control group received routine pharmacotherapy alone, while the experimental group received TIP technique as an add-on intervention based on the same pharmacotherapy with a treatment course of 3 months. Anxiety scores, electrocardiogram (ECG), liver and kidney function, and hematological parameters were compared between groups at each post-treatment time point. Analysis of variance, Kruskal-Wallis H, and Mann-Whitney tests were used for analysis.

Results

After treatment, Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale scores in the experimental group were significantly decreased compared with those in the control group at 2 and 3 months post-treatment (p<0.017). The incidence of abnormal ECG in the experimental group was significantly lower than that in the control group (p=0.017). All the indicators of the experimental group were lower than those of the control group. Hemoglobin and neutrophil-to-lymphocyte ratio in the experimental group were significantly higher than those in the control group at 3 months (p<0.017).

Conclusion

TIP as an add-on intervention can significantly reduce the incidence of abnormal ECGs and the damage to liver and kidney function, alleviate symptoms of depression and anxiety in adolescent patients.

INTRODUCTION

Depression is a highly prevalent mental health condition worldwide. It is clinically characterised by a persistently low mood, a diminished interest in activities, reduced energy, and impaired cognitive function. This disease is marked by low remission rates, high suicide risk and a tendency to relapse, which imposes a heavy burden on individuals, families and society [1]. Globally, more than 264 million individuals suffer from depression, including an estimated 50-60 million in China [2]. Research suggests that 3%-8% of adolescents exhibit varying degrees of depressive symptoms. In the absence of timely intervention, these symptoms may escalate to life-threatening behaviours such as self-harm or suicide, which pose a significant threat to adolescents’ mental health and wellbeing [3,4]. Current pharmacological treatments for adolescent depression and anxiety, such as sertraline, are often associated with prescribed side effects such as insomnia, dizziness, headaches, diarrhea, and potentially severe adverse reactions like atrioventricular block, arrhythmia, ventricular tachycardia (including intermittent torsades de pointes), and bleeding [5,6]. Improving treatment efficacy and reducing recurrence are critical priorities in adolescent mental health care.
Depression, as a complex mental disorder, has yet to be fully elucidated in its pathogenesis. As clinical research on depression has progressed, it has become increasingly clear that, in addition to biological factors, social and psychological elements are closely associated with the onset, progression and recurrence of the condition. Numerous national treatment guidelines for depression and related research data suggest that both antidepressant pharmacotherapy and psychotherapy are considered first-line treatments for all forms of depression. Clinical practice has demonstrated that psychological interventions positively enhance treatment efficacy in patients with depression, while also reducing recurrence rates. Psychotherapy can address predisposing factors in individuals with depression; over time, its long-term effectiveness may surpass that of pharmacological therapies. Low resistance state thought induction psychotherapy (TIP) is an innovative therapeutic approach employing various “form and spirit co-therapy” techniques to provide targeted psychotherapeutic interventions based on human psychological development and disease progression as therapeutic objectives [7]. As a localized system for psychological treatment, the TIP technique was developed by Professor Weidong Wang, drawing on more than 30 years of clinical experience [8]. This study specifically designed a parental involvement component to address family relationships as a core stressor for adolescents, with the aim of making TIP particularly suitable for adolescent depression. In the trauma re-experiencing phase, they used academic setbacks, and conveyed complex concepts through visual metaphors. Compared to the previous insomnia study, the adolescent version of TIP was shortened from 16 weeks to 12 weeks and an additional component to rebuild relationships with peers was included [8]. Currently, there exists a limited number of practical studies and evaluations regarding the clinical efficacy of this therapeutic modality. It is important to investigate the clinical effects of TIP interventions alongside standard pharmacological treatments for depression and anxiety in adolescents. The study aims to identify early, safe and effective therapeutic strategies to enhance clinical outcomes for adolescents experiencing these mental health challenges.

METHODS

Patients of study

A total of 100 adolescent patients with depression and anxiety who were admitted to our hospital from 2022 to 2023 were selected for the study. Inclusion criteria: 1) clinically diagnosed depression or anxiety (Diagnostic and Statistical Manual of Mental Disorders-5th Edition, DSM-5) conforms to the Structured Clinical Interview for DSM-5 for depression [9] 2) adolescents aged 12-18; 3) able to comprehend psychotherapy content; and 4) no treatment within 6 months. Exclusion criteria: 1) active suicidal plans requiring emergency intervention; 2) psychotic symptoms (hallucinations/delusions) or organic brain disorders; and 3) patients with serious physical diseases, endocrine diseases or serious organic diseases.
This was a single-center randomized controlled trial. Randomised group assignment using permutated block randomisation (block size=4) ensured balanced group sizes. Initially, 108 participants were enrolled. Withdrawal from the control group by four participants occurred (two due to dizziness, two lost to follow-up), and withdrawal from the experimental group by four (three relocated, one withdrawal). The final analysis included 50 participants in each group. The basic data of the patients were shown in Table 1, and a comparative analysis of clinical indicators revealed no significant differences between the experimental group and the control group (p>0.05). This study has been approved by the Medical Ethics Committee of The Second People’s Hospital of Gansu Province, approval number: ((2022) Ethical Review No.05) and was registered in the Chinese Clinical Trial Registry (ChiCTR; ChiCTR2600119490). All methods were carried out in accordance with Declaration of Helsinki. All participants provided written informed consent.

Treatment and methods

Patients in this group were treated with conventional therapy and TIP intervention therapy, respectively, and the clinical efficacy of the different cycles was analyzed and evaluated, and the efficacy of the different methods was compared and analyzed.

Control

Control group patients were treated with conventional drugs: sertraline hydrochloride (Zhejiang Huahai Pharmaceutical, H20080141) orally, the initial dose was 25 mg once a day, followed by 50 mg daily increments, gradually increasing to a maximum of 200 mg daily for 3 months. Sertraline was selected as the single antidepressant for the control group because it is the most widely recommended first-line pharmacotherapy for adolescent depression and anxiety in international and Chinese clinical guidelines [10,11]. To maintain a clean, standard, and comparable control condition, we used guideline-based monotherapy rather than sequential or combined treatment, which would introduce confounding variables and complicate the interpretation of TIP’s specific effect.

Experimental

Patients in the experimental group received TIP therapy in addition to the control group treatment strategy. Each 90-minute, weekly therapy was repeated for three consecutive months, for a total of 12 times. The following 12 projects will be carried out (Figure 1):
1) Medical history collection: gather fundamental information about a patient’s condition through diagnostic assessments and interactive questioning, while also gaining insight into their negative experiences.
2) The establishment of a TIP low-impedance: using the language of TIP therapy facilitates patient relaxation and encourages individuals to enter a low-impedance state.
3) Medical history review: through effective communication, patients are encouraged to reflect on their negative experiences. This includes recalling instances associated with the onset of their anxiety and depression, identifying factors that exacerbated these conditions.
4) The re-experiencing of the traumatic process: by directing patients to relive painful experiences associated with their initial emotional outbursts, we can gain a deeper understanding of their traumatic processes. Re-experiencing emotional surges enables patients to confront the psychological harm and impact such emotions can have on their well-being.
5) Event emotion stripping: analyze the underlying causes of negative emotions and their detrimental effects on the patient’s work, daily life, academic pursuits, and other areas. This understanding will help patients recognize that the adverse effects of negative emotions are ultimately unproductive. In addition, it is designed to assist patients in gaining a deeper insight into their emotional needs.
6) Analysis and cognitive comprehension: patients were instructed to analyze their negative emotions and correct erroneous thoughts, feelings, and thought patterns associated with these emotions. Additionally, the influence of the patient’s parents on their emotional experience was examined.
7) Reflections on negative emotions: hypnotic patients are guided to recall past negative emotions and experience them once more. This process allows patients to feel, express, and release their emotions in a safe environment. Through this therapeutic approach, they can rebuild their confidence and foster a positive outlook for the future.
8) Environmental adaptation experience: recollections of the patient’s negative emotional experiences are facilitated, allowing them to re-engage with reality. Involve the patient’s parents in the process to foster a supportive, coordinated environment.
9) Confidence enhancement: encourage patients to envision a better life and foster their confidence. Gradually alleviate and remove past traumas and sorrows of the patient.
10) Behavior guidance: the maladaptive behaviors of patients are addressed in real-world settings to facilitate their ongoing self-rehabilitation.
11) Refinement of preventive treatment: targeted counseling for patients to manage the recurrence of negative emotions is essential. It is important to emphasize the role of parents and the home environment in the treatment process.
12) End of treatment: gently rouse the patient to facilitate the completion of the treatment.

Observation index

Evaluation of Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale

Evaluate the patient’s depression and anxiety status pretreatment and at 1, 2, and 3 months post-treatment. The severity of depressive symptoms in patients was evaluated using the Hamilton Depression Rating Scale (HAMD) [12] and the Hamilton Anxiety Rating Scale (HAMA) [13]. HAMA total score evaluation of anxiety: no anxiety, <7; mild anxiety, 7-13; moderate anxiety, 14-20; severe anxiety, 21-28; extreme anxiety, ≥29. HAMD total score evaluation of depression: no depression, <8; mild depression, 8-19; moderate depression, 20-34; severe depression, ≥35.

Electrocardiogram

Electrocardiogram (ECG) evaluations were performed pretreatment, at 1 month and 3 months post-treatment. A standard 12-lead electrocardiograph (Foton FX-7402 model, Fukuda Denshi) was utilized for the synchronous recording of ECGs, with a voltage setting of 10 mm/mV and a paper speed set at 25 mm/s. Abnormal ECG findings, including sinus tachycardia, sinus bradycardia, atrial fibrillation, atrial premature beats, and premature ventricular contractions were documented.

Liver and kidney function

A total of 5 mL of fasting venous blood was collected from the right elbow of patients pre-treatment, at 1 month and 3 months post-treatment. Following centrifugation, the supernatant was obtained, and the expression levels of liver and kidney function indices were evaluated using an automatic analyzer (Mindray BS-600M, Mindray Medical International Limited). The measured parameters included alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, creatinine, blood urea nitrogen (BUN), and uric acid.

Routine blood test

Pre-treatment, at 1 month and 3 months post-treatment, 3 mL of fasting venous blood was collected from the right elbow of patients in both groups during the morning. Following centrifugation to obtain the supernatant, routine blood indices were analyzed using an automatic analyzer (Mindray BS-600M). The parameters evaluated included white blood cell count, hemoglobin (Hb), and neutrophil-to-lymphocyte ratio (NLR).

Statistical

The outcome assessment team for the HAMD/HAMA scales and the laboratory technicians analysing the blood samples and ECGs were blinded to group allocation. However, therapists could not be blinded due to the nature of psychotherapy. All statistical analyses were performed using IBM SPSS 22.0 software (IBM Corp.). Normality of continuous data was tested using the Shapiro-Wilk test. Measurement data that conformed to a normal distribution (Shapiro-Wilk p>0.05), including age, HAMD, HAMA, ECG parameters, liver and kidney function indices, Hb, and platelet-to-lymphocyte ratio, were expressed as mean±standard deviation (mean±SD). The primary efficacy outcome was defined as between-group comparison of absolute HAMD and HAMA scores at each post-treatment time point. Differences between two groups were evaluated using the independent-samples t-test, while differences among three or more groups were evaluated with one-way analysis of variance (ANOVA). For measurement data that did not conform to a normal distribution, results were presented as median (quartile), and the Kruskal-Wallis H test was employed to analyze differences among three or more groups. The Mann-Whitney U test was used for comparison between the two groups. Categorical data were reported as number of cases (percentage), and differences were analyzed using the χ2 test or Fisher’s exact test where appropriate. Bonferroni correction was applied for multiple comparisons across the three primary outcome domains. The significance level was adjusted to p<0.05/k, where k=3 represents the three primary outcome domains tested between groups (HAMD, HAMA, and ECG abnormality incidence). Thus, p<0.017 was considered statistically significant after correction. All statistical tests were two-sided.

Study limitations

This is a single-center randomized controlled trial with a relatively small sample size (n=100), which may limit generalizability. The follow-up duration was only 3 months; long-term efficacy and relapse rates beyond 6 months require further validation. Therapists were not blinded to group allocation, which may introduce performance bias in subjective outcomes. Only adolescents aged 12-18 years were included; results may not apply to younger children or older populations. The control group received pharmacotherapy alone without additional psychological contact time or attention control intervention. Therefore, the observed benefits may be partly attributed to non-specific attention effects rather than specific effects of TIP technique itself.

RESULTS

Comparison of HAMD and HAMA scores pre- and post-treatment

Repeated-measures ANOVA showed that both HAMA and HAMD scores were significantly reduced after treatment in both groups (p<0.05) (Tables 2 and 3). Between-group comparisons revealed that HAMD scores in the experimental group were significantly lower than those in the control group at 2 and 3 months post-treatment (p<0.001). For HAMA, significant between-group differences were observed at 2 months (p<0.001) and 3 months (p=0.005). However, the between-group differences at 1 month for both HAMA (p=0.030) and HAMD (p=0.026) did not reach statistical significance after Bonferroni correction (adjusted threshold p<0.017) (Tables 2 and 3).

ECG abnormality detection

Statistical analysis of abnormal ECG results for the two patient groups was conducted pre-treatment, at 1 month and 3 months post-treatment (Table 4). The incidence of abnormal ECGs in both groups after 1 month and 3 months of treatment did not reveal a significant difference within the control group (p=0.658). However, the incidence of abnormal ECG in the experimental group after 3 months was significantly lower than that observed after 1 month (p=0.012) (Supplementary Table 1). The results indicated that there was no significant difference in the incidence of abnormal ECG between the two groups pre-treatment and 1 month post-treatment (p>0.05). However, after 3 months of treatment, the incidence of abnormal ECGs in the experimental group was significantly lower than that observed in the control group (p=0.017) (Table 4). Furthermore, following treatment, the overall incidence of abnormal ECGs in the experimental group was markedly reduced compared to that in the control group (p<0.001) (Supplementary Table 2).

Detection of abnormal liver and kidney function

Absolute values of liver and kidney function indices at each post-treatment time point were compared between groups. Compared with the control group, after 1 month of treatment, AST in the experimental group was significantly lower (p=0.010). After 3 months, ALT, AST, and BUN in the experimental group were significantly lower than those in the control group (p<0.017) (Table 5). No significant changes were observed in the experimental group after treatment, while ALT, AST, and BUN in the control group were significantly decreased (p<0.001) (Supplementary Table 3).

Routine blood test results

Between-group comparisons of absolute values at 3 months showed that Hb and NLR in the experimental group were significantly higher than those in the control group (p<0.017) (Table 6). All the blood routine indicators of the experimental group and the control group were within the clinical normal reference range.

DISCUSSION

There is no doubt that depression and anxiety have become psychological health issues for adolescents as they grow up. Globally, about 9.1% of teenagers suffer from anxiety or depression [14]. In some regions, the detection rate of anxiety among teenagers can reach 34.6%, and the detection rate of depression can reach 39.51% [15,16], all of these numbers are still on the rise. The limitations of current clinical pharmacological treatments indicate that when addressing adolescent patients suffering from depression and anxiety, it is essential to focus not only on the patient’s adverse emotions and symptoms but also on the effects of ongoing “physical and psychological treatment” on their emotional well-being.
Numerous national guidelines for the treatment of depression, together with relevant research data, recommend that both antidepressant medication and psychotherapy be considered first-line treatment options for any form of depression [17,18]. Clinical practice has demonstrated that psychological interventions positively affect the efficacy of treatment for depressive disorders while simultaneously reducing the likelihood of relapse [19]. Psychotherapy can address underlying psychological vulnerabilities with depression, and its long-term efficacy may exceed that of pharmacological therapies [20]. It is essential to acknowledge that various aspects of psychotherapy are intricately linked to cultural contexts and exhibit specific regional characteristics. At present, however, the most prevalent forms of Western psychotherapy are not closely aligned with Chinese cultural paradigms, resulting in significant shortcomings and limitations when applied to the Chinese population [21]. Therefore, it is of substantial clinical importance to investigate and develop localized psychotherapeutic approaches tailored to Chinese individuals.
As a traditional integrative psychotherapy, TIP represents a localized therapeutic model that is attuned to the Chinese national context. Research has shown that TIP technique-assisted therapy is both effective and safe in alleviating symptoms of depression and anxiety in clinical patients [22-24]. The therapeutic mechanism of TIP may involve coordinated regulation of neuroendocrine, autonomic nervous, inflammatory and psychosocial dimensions [25,26]. Rooted in the Chinese holistic concept of form and spirit harmony, TIP induces a low-resistance state to modulate sympathetic overexcitation, attenuate negative emotion-related somatic arousal, and ameliorate stress-related cardiac electrical disturbances. It remodels abnormal stress feedback loops, suppresses HPA (hypothalamic-pituitary-adrenal) axis hyperactivity, relieves chronic stress-induced visceral burden, and reverses stress-mediated elevations of ALT, AST, and BUN. Additionally, TIP improves emotional regulation and cognitive reappraisal, alleviates persistent psychological stress, and optimizes systemic inflammatory and hematological profiles (e.g., elevated Hb, improved NLR balance). For adolescents, the culturally adapted TIP incorporates family participation and interpersonal reconstruction to buffer family stressors, consolidate social support, and maintain emotional stability. Collectively, these multi-pathway effects alleviate core depressive and anxious symptoms, while improving key physiological and inflammatory indicators and enhancing social support. To achieve these therapeutic effects, the TIP treatment system employs a “form and spirit co-treatment” methodology that encompasses relaxation techniques, hypnotherapy, behavioral adjustments, and emotional regulation strategies, among others [27]—methods that further assist patients in alleviating negative emotions, redirecting attention away from somatization symptoms to a certain extent, and enhancing their confidence and enthusiasm for clinical treatment.
Based on the fundamental implementation principles of the TIP technique, this study refines and optimizes various aspects of the TIP intervention, involving the patient’s parents and addressing the impact of the home environment on the patient’s negative emotions. Partial blinding (where therapists are aware of the treatment group) may introduce performance bias in behavioural outcomes, though its impact on objective measurements (ECGs and blood tests) was mitigated by assessment blinding. The results demonstrated that the combined TIP and sertraline intervention yielded superior outcomes relative to standard pharmacotherapy alone in terms of blood routine safety and minimization of liver and kidney damage. Notably, after 3 months of pharmacotherapy alone, the reduction rates of HAMD and HAMA scores in the control group were both less than 40%, indicating relatively insufficient efficacy of sertraline monotherapy in this sample. This observation is consistent with real-world evidence that many adolescents exhibit partial or poor response to antidepressant monotherapy [28]. Sequential treatment (e.g., medication switching or combination) was not adopted in this study because the primary aim was to evaluate the add-on efficacy and safety of TIP technique based on a stable, consistent, first-line pharmacotherapy platform. Using sequential treatment would have introduced variability in medication management and undermined the ability to isolate the specific effect of TIP. The low reduction rate in the medication-only group further highlights the clinical necessity and value of adjuvant psychological interventions such as TIP for adolescent depression and anxiety.
Improvements in biomarkers suggest a reduced pharmacological burden in the TIP group, rather than direct therapeutic efficacy. In addition, the alleviation of symptoms of depression and anxiety in adolescents and the offer of improved safety are further benefits of this therapy. The targeted development and optimization of TIP technical interventions holds considerable promise for the clinical management of depressive and anxiety symptoms in adolescents, opening new avenues for the treatment of locally depressed patients. The efficacy of TIP during the acute phase has been confirmed by this 3-month randomized controlled trial. Management of the chronic phase requires long-term studies of at least 12 months to evaluate relapse rates and develop intensive maintenance therapy regimens. Further research is needed to investigate the durability of efficacy beyond 6 months.
In addition, this study has limitations in the control design of non-specific therapeutic factors. The control group only received standard pharmacotherapy without matched contact time, supportive attention, or psychological placebo intervention. Thus, the favorable outcomes of the experimental group cannot be fully attributed to the specific mechanism of TIP; non-specific attention effects, therapeutic alliance, and more frequent therapist-patient contact may also contribute to clinical improvements. Furthermore, the lack of a TIP-monotherapy subgroup limits the ability to distinguish the independent efficacy of TIP from its additive effect combined with sertraline. This design arrangement was mainly due to ethical concerns that adolescents with moderate to severe depression and anxiety require guideline-based first-line pharmacotherapy, as well as sample size and feasibility restrictions. Future studies should establish an attention control or supportive counseling group to balance contact intensity, and adopt a three-arm design including TIP monotherapy and combined treatment subgroups, to more rigorously verify the specific efficacy of TIP on psychological symptoms, ECG changes, and liver and kidney function indicators.
In conclusion, this randomized controlled trial demonstrates that TIP exhibits preliminary efficacy in alleviating psychiatric symptoms among adolescent patients while maintaining good safety, indicating its potential as an adjunctive treatment for depressive and anxiety in adolescents. However, its long-term benefits require further validation.

Supplementary Materials

The Supplement is available with this article at https://doi.org/10.30773/pi.2025.0163.
Supplementary Table 1.
Comparison of abnormal ECG after treatment
pi-2025-0163-Supplementary-Table-1.pdf
Supplementary Table 2.
Comparison of abnormal ECG before and after treatment
pi-2025-0163-Supplementary-Table-2.pdf
Supplementary Table 3.
The comparison of abnormal liver and kidney function index differences between the two groups following treatment was conducted
pi-2025-0163-Supplementary-Table-3.pdf

Notes

Availability of Data and Material

Data will be made available on request.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Yaqi Feng. Data curation: Rong Zhang. Formal analysis: Rong Zhang. Funding acquisition: Jingxia Zhang, Rong Zhang. Investigation: Lingyun Fan. Methodology: Yaqi Feng. Visualization: Rong Zhang. Writing—original draft: Yaqi Feng. Writing—review & editing: Jing Tang, Jingxia Zhang.

Funding Statement

This study was supported by Gansu Province Health and Wellness Industry Research Plan Project (grant no. GSWSKY2021-034, no. GSWSKY 2025-75).

Acknowledgments

None

Figure 1.
The TIP intervention process. TIP, thought induction psychotherapy.
pi-2025-0163f1.jpg
Table 1.
Baseline characteristics of the study participants
Control (N=50) Experimental (N=50) Statistical value p
Sex χ2=0.667 0.414
 Male 18 (36.00) 22 (44.00)
 Female 32 (64.00) 28 (56.00)
Age (yr) 14.74±2.06 14.88±1.97 t=0.348 0.729
Course of disease (yr) 0.66±0.12 0.65±0.26 t=0.346 0.730
Education χ2=0.650 0.723
 Junior high school 17 (34.00) 20 (40.00)
 Senior high school/secondary 25 (50.00) 21 (42.00)
 College or above 8 (16.00) 9 (18.00)
Type of disease χ2=0.219 0.640
 First episode 37 (74.00) 39 (78.00)
 Recrudescence 13 (26.00) 11 (22.00)

Values are presented as mean±standard deviation or N (%).

Table 2.
Comparison of absolute HAMA scores at each time point between two groups
Group Duration of treatment (month)
0 1 2 3
Control (N=50) 14.20±2.54 11.82±1.98 10.62±2.08 10.08±3.39
Experimental (N=50) 14.38±2.36 10.76±2.76 8.74±2.13 8.44±2.27
 t 0.367 2.208 4.470 2.845
 p 0.715 0.030 <0.001 0.005

Values are presented as mean±standard deviation. HAMA, Hamilton Anxiety Rating Scale.

Table 3.
Comparison of absolute HAMD scores at each time point between two groups
Group Duration of treatment (month)
0 1 2 3
Control (N=50) 27.26±3.58 25.22±3.07 22.60±2.87 18.12±4.04
Experimental (N=50) 27.28±4.75 23.62±3.96 18.78±2.84 11.42±3.65
 t 0.024 2.261 6.683 8.693
 p 0.981 0.026 <0.001 <0.001

Values are presented as mean±standard deviation. HAMD, Hamilton Depression Rating Scale.

Table 4.
Abnormal ECG results of the patients
Duration of treatment (month) Clinical index Control (N=50) Experimental (N=50)
0 ST 4 (8.00) 2 (4.00)
SB 1 (2.00) 1 (2.00)
AF 3 (6.00) 3 (6.00)
APB 2 (4.00) 4 (8.00)
PVCs 7 (14.00) 6 (12.00)
1 ST 3 (6.00) 1 (2.00)
SB 2 (4.00) 2 (4.00)
AF 1 (2.00) 1 (2.00)
APB 1 (2.00) 1 (2.00)
PVCs 7 (14.00) 6 (12.00)
3 ST 1 (2.00) 1 (2.00)
SB 1 (2.00) 0 (0.00)
AF 2 (4.00) 0 (0.00)
APB 2 (4.00) 1 (2.00)
PVCs 7 (14.00) 2 (4.00)

Values are presented as N (%). ECG, electrocardiogram; ST, sinus tachycardia; SB, sinus bradycardia; AF, atrial fibrillation; APB, atrial premature beats; PVCs, premature ventricular contractions.

Table 5.
Abnormal liver and kidney function results of the patients
Duration of treatment (month) Clinical index Control (N=50) Experimental (N=50) t p
0 ALT (U/L) 24.10±2.08 24.06±1.90 0.100 0.920
AST (U/L) 23.62±2.43 23.72±2.13 0.219 0.827
ALP (U/L) 49.64±16.63 49.42±13.84 0.072 0.943
Cr (μmol/L) 75.86±8.44 75.04±8.89 0.473 0.637
BUN (mmol/L) 5.58±1.33 5.49±1.42 0.349 0.728
UA (μmol/L) 209.48±39.52 208.14±41.37 0.166 0.869
1 ALT (U/L) 25.52±2.07 24.98±2.61 1.144 0.255
AST (U/L) 25.34±2.35 24.24±1.77 2.643 0.010
ALP (U/L) 48.70±18.49 48.04±15.79 0.192 0.848
Cr (μmol/L) 75.38±9.61 76.18±9.57 0.417 0.677
BUN (mmol/L) 6.40±1.66 5.81±1.49 1.889 0.062
UA (μmol/L) 225.30±39.85 222.30±34.75 0.401 0.689
3 ALT (U/L) 33.32±8.75 24.18±2.34 7.137 <0.001
AST (U/L) 29.46±5.05 23.26±2.26 7.924 <0.001
ALP (U/L) 48.96±19.53 46.28±15.50 0.760 0.449
Cr (μmol/L) 76.36±12.32 74.56±13.09 0.708 0.481
BUN (mmol/L) 6.74±1.68 5.63±1.55 3.424 0.001
UA (μmol/L) 226.54±43.75 213.86±41.42 1.488 0.140

Values are presented as mean±standard deviation. ALT, alanine transaminase; AST, aspartate aminotransferase; ALP, alkaline phosphatase, Cr, creatinine; BUN, blood urea nitrogen; UA, uric acid.

Table 6.
Blood routine results of the patient
Duration of treatment (month) Clinical index Control (N=50) Experimental (N=50) t p
0 WBC (×109/L) 8.66±1.04 8.83±1.10 0.763 0.447
Hb (g/L) 123.62±10.92 123.94±10.75 0.148 0.883
NLR 3.71±0.48 3.58±0.36 1.504 0.136
PLR 102.12±11.51 102.62±10.88 0.223 0.824
1 WBC (×109/L) 8.47±0.84 8.38±0.38 0.702 0.484
Hb (g/L) 121.78±7.33 123.86±6.31 1.520 0.132
NLR 3.82±0.52 3.91±0.47 0.823 0.412
PLR 105.72±10.01 108.66±9.65 1.495 0.138
3 WBC (×109/L) 9.06±1.30 8.74±0.81 1.477 0.143
Hb (g/L) 123.34±10.30 131.06±10.29 3.749 <0.001
NLR 4.02±0.58 4.36±0.68 2.663 0.009
PLR 111.38±12.71 113.50±11.10 0.888 0.376

Values are presented as mean±standard deviation. WBC, white blood cell; Hb, hemoglobin; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

REFERENCES

1. World Health Organization. Guidelines on mental health at work. Geneva: World Health Organization; 2022.

2. Yu X, Jones RN, Kobayashi LC, Gross AL. Cross-national statistical harmonization of the center for epidemiologic studies depression (CESD) scale among older adults in China, England, India, Mexico, South Africa, and the United States. J Clin Epidemiol 2025;178:111623
crossref pmid pmc
3. Colburn MD, Harris E, Lehmann C, Widdice LE, Klein MD. Adolescent depression curriculum impact on pediatric residents’ knowledge and confidence to diagnose and manage depression. J Adolesc Health 2020;66:240-246.
crossref pmid
4. El-Etreby RR, Abdelraof AI. Effect of psycho-educational intervention on burden and quality of life among family caregivers of schizophrenic patients. J Health Med Nurs 2019;63:70-80.

5. Panariello F, Kasper S, Zohar J, Souery D, Montgomery S, Ferentinos P, et al. Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting. World J Biol Psychiatry 2023;24:439-448.
crossref pmid
6. Marasine NR, Sankhi S, Lamichhane R, Marasini NR, Dangi NB. Self-reported antidepressant drug side effects, medication adherence, and its associated factors among patients diagnosed with depression at the psychiatric hospital of Nepal. Depress Res Treat 2020;2020:7024275
crossref pmid pmc pdf
7. Yan X, Wang W, Liu Y, Wang J, Tang C. Efficacy of thought imprint psychotherapy for primary insomnia in adults: a randomized controlled trial. Sleep Med 2017;40(Supplement 1):e353.
crossref
8. Dippel N, Szota K, Cuijpers P, Christiansen H, Brakemeier EL. Family involvement in psychotherapy for depression in children and adolescents: systematic review and meta-analysis. Psychol Psychother 2022;95:656-679.
crossref pmid pdf
9. Cooper R. Diagnosing the diagnostic and statistical manual of mental disorders. Abingdon: Routledge; 2018.

10. Wu T, Song F, Cao W, Liu C, Jia S. Comparative efficacy of antidepressant medication for adolescent depression: a network meta-analysis and systematic review. BMC Psychiatry 2025;25:471
crossref pmid pmc pdf
11. Walter HJ, Abright AR, Bukstein OG, Diamond J, Keable H, Ripperger-Suhler J, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders. J Am Acad Child Adolesc Psychiatry 2023;62:479-502.
crossref pmid
12. Zhang J, Song Z, Gui C, Jiang G, Cheng W, You W, et al. Treatments to post-stroke depression, which is more effective to HAMD improvement? A network meta-analysis. Front Pharmacol 2022;13:1035895
crossref pmid pmc
13. Zhang W, Yan Y, Wu Y, Yang H, Zhu P, Yan F, et al. Medicinal herbs for the treatment of anxiety: a systematic review and network meta-analysis. Pharmacol Res 2022;179:106204
crossref pmid
14. Barker MM, Beresford B, Fraser LK. Incidence of anxiety and depression in children and young people with life-limiting conditions. Pediatr Res 2023;93:2081-2090.
crossref pmid pmc pdf
15. Shen Y, Zheng J, Shi Z, Sun M, Luo H, Cui Y, et al. [Investigation of anxiety and depression in children and adolescents in Chongqing]. J Int Psychiatry 2021;48:991-993. Chinese.

16. Xie X, Feng B, Li Y, Liang Y, Wang Y, Lin Y, et al. [Research on family factors related to adolescent depressive symptoms]. Chin J Child Health Care 2022;30:446-449. Chinese.

17. Mavranezouli I, Megnin-Viggars O, Pedder H, Welton NJ, Dias S, Watkins E, et al. A systematic review and network meta-analysis of psychological, psychosocial, pharmacological, physical and combined treatments for adults with a new episode of depression. EClinicalMedicine 2024;75:102780
crossref pmid pmc
18. Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2020;7:581-601.
crossref pmid pmc
19. Zhou Y, Zhao D, Zhu X, Liu L, Meng M, Shao X, et al. Psychological interventions for the prevention of depression relapse: systematic review and network meta-analysis. Transl Psychiatry 2023;13:300
crossref pmid pmc pdf
20. Cuijpers P, Quero S, Noma H, Ciharova M, Miguel C, Karyotaki E, et al. Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World Psychiatry 2021;20:283-293.
crossref pmid pmc pdf
21. Li J, Li J, Yuan L, Zhou Y, Zhang W, Qu Z. Cultural adaptation of trauma-focused cognitive behavioral therapy for trauma-affected children in China. Psychol Trauma 2024;16(Suppl 3):S472-S482.
crossref pmid
22. Weidong W, Haisheng Z, Hui D. The latest development of low resistance thought imprint psychotherapy sleep-regulating technique of insomnia. Sleep Med 2013;14(Suppl 1):e148.
crossref
23. Li S, Zhong X, An L, Ran C. [Effect of TIP technique on coke, depression and sleep quality in patients with chronic kidney disease]. Heilongjiang Med J 2021;34:292-294. Chinese.

24. Zheng LM, Mai JY, Yang DR, Zhan Z, Li Y, Wang WD. [Observation on the efficacy of TCM psychological TIP technique and Chinese medicine acupuncture intervention in patients with mild to moderate depression]. J Tradit Chin Med Res 2019;30:2683-2685. Chinese.

25. Lv X, Lu F, Zhang J, Chen H, Zhang L, Wang X, et al. Effects of TIP treatment on brain network topology of frontolimbic circuit in first-episode, treatment-naïve major depressive disorder. J Affect Disord 2021;279:122-130.
crossref pmid
26. Lu F, Zhang J, Zhong Y, Hong L, Wang J, Du H, et al. Neural signatures of default mode network subsystems in first-episode, drug-naive patients with major depressive disorder after 6-week thought induction psychotherapy treatment. Brain Commun 2024;6:fcae263
crossref pmid pmc pdf
27. La Rocque CL, Mazurka R, Stuckless TJR, Pyke K, Harkness KL. Randomized controlled trial of bikram yoga and aerobic exercise for depression in women: efficacy and stress-based mechanisms. J Affect Disord 2021;280(Pt A):457-466.
crossref pmid
28. Alemi F, Soylu TG, Cannon M, McCandless C. Effectiveness of antidepressants in combination with psychotherapy. J Ment Health Policy Econ 2024;27:3-12.
pmid


ABOUT
AUTHOR INFORMATION
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
Editorial Office
#522, G-five Central Plaza, 27 Seochojungang-ro 24-gil, Seocho-gu, Seoul 06601, Korea
Tel: +82-2-537-6171  Fax: +82-2-537-6174    E-mail: psychiatryinvest@gmail.com                

Copyright © 2026 by Korean Neuropsychiatric Association.

Developed in M2PI

Close layer
prev next